Experts in Conversation: Highlights from CTAD 2024 – 1 with Charlotte Teunissen and Craig Ritchie | Journey to a New Era for Alzheimer’s Disease
Released On
April 3, 2024
Expires On
November 30, 2025
Media Type
Internet
Completion Time
20 minutes
Specialty
Geriatric Medicine, Neurology, Psychiatry
Topics
Alzheimer's, Dementia
This activity is supported by an educational grant from Lilly.
Credit Available
- Physicians — 0.25 AMA PRA Category 1 Credits™
Target Audience
Global neurologists, geriatricians and geriatric psychiatrists. The program content will be suitable for gerontologists as well as nurse practitioners and physician assistants who are involved in the care of patients with AD.
Program Overview
2024 brought pivotal advances in neurodegenerative biomarkers for early Alzheimer’s detection, insights into amyloid-targeted therapies and patient selection, and new strategies for ARIA risk assessment and management.
Revisit 2024 Conference Highlights for Alzheimer’s Disease. Watch Experts in Conversation: Highlights from CTAD 2024 – 1, featuring Charlotte Teunissen (The Netherlands) and Craig Ritchie (UK).
This program is part of the larger initiative, Journey to a New Era for Alzheimer’s Disease. Register for free to access news articles, video highlights, accredited expert discussions, concise research summaries, podcasts, and interactive quizzes to test your knowledge: https://new-era-alzheimers-disease.ime.springerhealthcare.com/.
Learning Objectives
After participating in this program, you will be able to:
- Endorse the importance of a proactive and accurate diagnosis of early-stage AD
- Evaluate the rationale and utility of current and emerging biomarkers within the current diagnostic work-upp
- Identify which patients would most benefit from amyloid-targeted therapy use through the analysis of the most current data
- Appraise the current understanding around risk factors, detection methods, and management approaches for ARIA
Faculty
Professor Charlotte Teunissen
Program Director
Professor of Neurochemistry, Chair of Neurochemistry Lab, Amsterdam UMC, The Netherlands
Professor of Neurochemistry, Chair of Neurochemistry Lab, Amsterdam UMC, The Netherlands Charlotte Teunissen’s drive is to improve care of patients with neurological diseases by developing body fluid biomarkers for diagnosis, stratification, prognosis and monitoring treatment responses. Studies of her research group span the entire spectrum of biomarker development, starting with biomarker identification, often by –omics methods, followed by biomarker assay development and analytical validation, and lastly, extensive clinical validation and implementation of novel biomarkers in clinical practice.
She has extensive expertise with assay development on state-of-the-art technologies, such as mass spectrometry and antibody-based arrays for biomarker discovery, ultrasensitive immunoassays, and in implementation of vitro diagnostic technologies for clinical routine lab analysis. She is responsible for the large well-characterized biobank of the Amsterdam Dementia cohort, containing >10,000 paired CSF and serum samples of individuals visiting the memory clinic of the Alzheimer Center Amsterdam (a.o. controls, patients with Alzheimer, Frontotemporal, Lewy Bodies). To ensure the quality of the biosamples, the group studies pre-analytical effects, which are key to implementation.
Prof Teunissen is leading several collaborative international biomarker networks, such as the Society for Neurochemistry and routine CSF analysis and the Alzheimer Association-Global Biomarker Standardization and Blood Based Biomarkers and the Body fluid Biomarkers PIA, and the recently founded Coral proteomics consortium. She is the coordinator of the Marie Curie MIRIADE project, aiming to train 15 novel researchers into innovative strategies to develop dementia biomarkers (10 academic centers + 10 non-academic centers), and the JPND bPRIDE project, that aims to develop targeted blood-based biomarker panels for early differential diagnoses of specific dementias and is a collaborative project between 7 European and 1 Australian centers.
Amsterdam, The Netherands
Professor Craig Ritchie
Professor of Brain Health and Neurodegenerative Medicine, University of St Andrews, Scotland
Craig Ritchie is Founder and CEO of Scottish Brain Sciences and Professor of Brain Health and Neurodegenerative Medicine at the University of St Andrews, having moved from his role as Senior Lecturer in the Centre for Mental Health at Imperial College London in October 2014. He completed his PhD at UCL through an MRC Health Services Research Fellowship and was appointed as Senior Lecturer in Old Age Psychiatry at Imperial College London in 2007. He has also served as R&D Director at West London Mental Health Trust from 2010-14 and Deputy Director of the London Northwest NIHR Clinical Research Network. In 2014 he was appointed as Chair in Psychiatry of Ageing at the University of Edinburgh. In 2015 he established the Centre for Dementia Prevention and that year took on the academic leadership role of the EPAD (European Prevention of Alzheimer’s Dementia) Programme. Between 2017 and 2022 he was the elected Chair of the Scottish Dementia Research Consortium and in 2020 he founded and was the inaugural Directorof Brain Health Scotland. He has published over 400 academic papers, conference abstracts and book chapters and secured approximately €100M of grant funding in his career to date.
His main research interest is the interface between clinical trials and translational epidemiology (cohort studies) with a drive to develop the infrastructures at a national level (in Scotland) to prepare health systems and prosecute rapid ‘research into practice’ programmes. He is a pioneer and leading advocate for the Brain Health Movement that works across the life course from primary to secondary prevention of late-stage neurodegenerative disease. This involved working at a public health and policy level as well as developing and implementing Brain Health Clinics across Scotland following ‘The Scottish Model for Brain Health Services’. This work has led Scotland to being one of the Flagship Countries in the Davos Alzheimer’s Collaborative for Health Care Readiness.
He established Scottish Brain Sciences in summer 2022 to accelerate the development of both diagnostics and therapeutics for early-stage neurodegenerative disease and moved full time into the role of CEO of this company in January 2023.
St. Andrews, Scotland
Accreditation Statement
Credits Available
Completing one Expert in Conversation activity will earn you 0.5 AMA PRA Category 1 Credits™. The activity for CTAD is separated into 2 videos and you will need to watch both to earn 0.5. You can earn a total of 1.5 credits for all four activities.
In support of improving patient care, this activity has been planned and implemented by Postgraduate Institute for Medicine and Springer Healthcare IME. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
As part of the planning committee Rebecca Cox and Jules Morgan have no interests to disclose.
Disclosures of Conflicts of Interest
Professor Charlotte Teunissen
Charlotte E. Teunissen is employed by Amsterdam UMC. She has grants or contracts for Research of the European Commission (Marie Curie International Training Network, grant agreement No 860197 (MIRIADE), Innovative Medicines Initiatives 3TR (Horizon 2020, grant no 831434) EPND ( IMI 2 Joint Undertaking (JU), grant No. 101034344) and JPND (bPRIDE), National MS Society (Progressive MS alliance), Alzheimer Drug Discovery Foundation, Alzheimer Association, Health Holland, the Dutch Research Council (ZonMW), including TAP-dementia, a ZonMw funded project (#10510032120003) in the context of the Dutch National Dementia Strategy, Alzheimer Drug Discovery Foundation, The Selfridges Group Foundation, Alzheimer Netherlands. She is recipient of ABOARD, which is a public-private partnership receiving funding from ZonMW (#73305095007) and Health~Holland, Topsector Life Sciences & Health (PPP-allowance; #LSHM20106). She is also a contract researcher for ADx Neurosciences, AC-Immune, Aribio, Axon Neurosciences, Beckman-Coulter, BioConnect, Bioorchestra, Brainstorm Therapeutics, Celgene, Cognition Therapeutics, EIP Pharma, Eisai, Eli Lilly Fujirebio, Grifols, Instant Nano Biosensors, Merck, Novo Nordisk, Olink, PeopleBio, Quanterix, Roche, Siemens, Toyama, Vivoryon, and the European Commission. She has received payment or honoraria from Roche, Novo Nordisk, and Grifols, where all payments were made to her institution. She also serves on editorial boards of Medidact Neurologie/Springer; and in Neurology: Neuroimmunology & Neuroinflammation. She is editor of Alzheimer Research and Therapy.
Professor Craig Ritchie
Craig Ritchie is the CEO, Founder, and majority shareholder of Scottish Brain Sciences. He has received consulting fees from Eisai, Eli Lilly, Biogen, MSD, Actinogen, AbbVie, Roche, and Novo Nordisk; and payment and honoraria for presenting at Roche and Eisai.
All relevant financial relationships have been mitigated.
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
- Read the CME/CE information and faculty disclosures.
- Participate in the online activity.
- Submit the evaluation form.
Your certificate will be made available for immediate download.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
Springer Healthcare IME requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
Disclaimer
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
Contact Information
For CE questions, please contact: [email protected].